Bicalutamide
Back to searchMolecule Structure
Scientific Name
Bicalutamide
Description of the Drug
Bicalutamide is an androgen receptor inhibitor used to treat Stage D2 metastatic carcinoma of the prostate.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01128
http://www.drugbank.ca/drugs/DB01128
Brand Name(s)
Bicalutamide, Calutide, Casodex, Cosudex, Kalumid
Company Owner(s)
Apotex Inc, Teva Pharmaceuticals Usa Inc, Kenton Chemicals And Pharmaceuticals Corp, Fresenius Kabi Usa Llc, Sandoz Inc, Watson Laboratories Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc, Sun Pharmaceutical Industries Ltd, Synthon Pharmaceuticals Inc, Accord Healthcare Inc, Roxane Laboratories Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Androgen Receptor | SINGLE PROTEIN | ANTAGONIST | CHEMBL1871 |
Clinical Trial(s)
Unichem Links
| Atlas | bicalutamide | |
| SureChEMBL | SCHEMBL3611 | |
| PharmGKB | PA164746255 | |
| Human Metabolome Database | HMDB0015260 | |
| DrugBank | DB01128 | |
| PubChem: Thomson Pharma | 14807515 | |
| PubChem | 2375 | |
| LINCS | LSM-1437 | |
| Nikkaji | J636.420I | |
| BindingDB | 18525 | |
| EPA CompTox Dashboard | DTXSID2022678 | |
| DrugCentral | 367 | |
| ChemicalBook | CB7457827 | |
| Guide to Pharmacology | 2863 | |
| rxnorm | BICALUTAMIDE | CASODEX |
| PubChem: Drugs of the Future | 12014029 | |
| ChEBI | 144093 |
